One of the frustrating symptoms of multiple sclerosis (MS) is cognitive decline. Many patients have trouble with concentration, judgment and memory. Researchers wanted to learn if a drug that's effective with early dementia may help MS patients.

Gilenya , a FDA-approved multiple sclerosis drug, had positive results in a late-stage clinical trial. The results may help ease safety concerns about the drug.

What causes multiple sclerosis? There's been a lot of speculation, but few definitive answers. Researchers now believe they've found a troublesome gene that may cause MS in some patients.

A new medication for multiple sclerosis just got one step closer to being available for use. Researchers have published data that they believe shows exactly how the drug works in the brain.

Multiple sclerosis manifests in a wide range of symptoms, from difficulty with balance to fatigue and vision problems. These problems all originate in the brain, but how?

If you have multiple sclerosis, will drinking wine make the disease worse? How about smoking? Or eating fish? How do daily choices affect your condition?

Have you ever gone to the grocery store and forgotten an item you went there to get? A technique used to improve learning and memory in multiple sclerosis patients may help you, too.

Primary progressive multiple sclerosis (PPMS) has no established course of treatment. But follow up results from a drug trial provide a glimmer of hope for patients.

Dealing with a debilitating disease is challenging on its own. Add depression on top of it, and the burden of disease is crippling. For many patients with MS, that's reality.

A new drug for multiple sclerosis (MS) has shown promising results in clinical trials. The drug, called ocrelizumab, has a novel new target to treat the disease.